Stockreport

Xilio Therapeutics Announces New Preclinical Data at AACR Annual Meeting for XTX601, a Masked T Cell Engager Targeting CLDN18.2

Xilio Therapeutics, Inc.  (XLO) 
PDF XTX601 demonstrated protease-dependent, tumor-selective activation and potent anti-tumor activity in multiple preclinical models  Consistent with Xilio’s clinically-val [Read more]